Haselmeier, Common Sensing to Partner on Injectable Solutions

Article

The companies will partner to develop smart connected monitoring and support solutions for injectable drugs.

On May 3, 2018, Haselmeier, a Swiss-based developer and manufacturer of self-injection devices, and Common Sensing, a Cambridge, MA-based smart injector monitoring and support solutions company, announced a partnership to develop smart connected monitoring and support solutions for injectable drugs. 

Haselmeier’s subcutaneous drug delivery injection systems for self-administration will be combined with Common Sensing’s Gocap injector monitoring technology to create a smart disposable injector pen platform, which will be available in 2019. The platform will be sold by Haselmeier. 

The smart injector pen will record the time and amount of every injector dose as well as other information, such as storage temperature. Gocap information may be made available for users, caretakers, clinicians, healthcare systems, researchers, and pharmaceutical companies, according to Haselmeiner.

“There is a high need to provide patients the means to better monitor the efficacy of their therapy and the injection experience is a crucial moment in a patient’s therapy. The collaboration of Haselmeier with Common Sensing is a smart and fast way to achieve our objective in improving patients’ lives,” said Frédéric Gabriel, chief strategy officer at Haselmeier, in a company press release.

Source: Haselmeier

Recent Videos
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
© 2024 MJH Life Sciences

All rights reserved.